Mentor to roll out PerImmune physician-office bladder cancer test kit this fall, CEO says.
This article was originally published in The Gray Sheet
Executive Summary
MENTOR TO BEGIN MARKETING PERIMMUNE PHYSICIAN OFFICE BLADDER CANCER TEST THIS FALL under a marketing agreement announced June 16 by Mentor Chairman and CEO Christopher Conway at a Piper Jaffray investment conference in Minneapolis. The pact provides Mentor with exclusive worldwide distribution rights to Rockville, Maryland-based PerImmune's urine-based immunoassay, which is intended for use in conjunction with cystoscopy to aid in the management of bladder cancer patients.
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.